AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05740397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Management of mean arterial pressure during cardiopulmonary by-pass in cardiac surgery interventions. The MAP will be mantained in the range of values of each study arm
Description: The patients enrolled to elective cardiac surgeries will be evaluated during a pre-operative outpatient visit and widely informed about the chance to participate in the study. When patients undergo to the elective surgery general anaesthesia is administered and CPB is installed. The nominal flow for each patient will be 2,4 l/min/m2.~To keep the MAP values around those corresponding to the randomized group, vasodilator (if MAP overcomes the assigned MAP value) or vasoconstrictor drugs will be used (if MAP value is lower than the assigned group). The following drugs will be used: nitroglicerine at incremental dose of 0,01 mcg/kg/min for a vasodilator effect and norepinephrine at incremental dose of 0,01 mcg/kg/min for a vasoconstrictor effect
Study NCT06106685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will be given equal volume placebo (120ml carrier solution matching the volume of WMT-001), which contains 10% sterile glycerol and saline injection. The drug was administered once a day for 4 days.
Study NCT05613491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin
Description: Put insulin injection into nasal special drug delivery device.Before anesthesia induction, give the first insulin nasal spray, once per hour, 20 IU each time, until the end of the operation
Study NCT05613491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal saline
Description: Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
Study NCT05064943 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2-minute step test
Description: The participant stands and counts for 2 minutes. The minimum height to raise the knee is determined for each participant by calculating the midpoint between the patella and the anterior superior iliac spine. They are instructed to complete as many steps as possible during the 2-minute period. A verbal command is given every 30 seconds to encourage performance: You're doing great, keep it up. If the claudication symptom becomes unbearable, the patient can stop during the test, but the time is not stopped. Patients who discontinue testing due to symptoms of claudication are encouraged to return to testing as soon as possible. An evaluator records the number of steps in the right leg.
Study NCT05283785 — intervention group
Intervention type: PROCEDURE
Intervention: End To End or End to side sutures
Description: End to end or End to side sutures of ulnar nerve by nerve to quadratus muscle ( branch of anterior interosseous nerve )
Study NCT06141889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelaprag
Description: oral, apelin receptor (APJ) agonist
Study NCT05143736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gut and nasal microbiota detection
Description: The nasal and fecal specimens will be collected by swabs from subjects with sepsis. After that, total DNA of nasal and gut microbiota will be extracted , amplified, and sequenced to determine the gut and nasal microbiota.
Study NCT04956276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1830
Description: Administered as an SC infusion.
Study NCT04956276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as an SC infusion.
Study NCT05398159 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trim II
Description: Eligible subjects will receive 3 bi-weekly treatments (once in 2 weeks) with Trim II hands-free applicator belt according to the study protocol.~Trim II hands-free applicator composed of 4 units applied to the abdominal area, using a single-use belt.~Each treatment duration will be 45-60 minutes. Study duration for each subject is approximately 6 months (including screening, 3 treatments and 2 follow-up visits at 1 and 3 months post last treatment).
Study NCT04866641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-1201 Injection 100 mg Kit
Description: T-1201 Injection 100 mg Kit contains lyophilized powder with a sterile aqueous solution formulated for intravenous administration.
Study NCT05356676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometrics
Description: Isometric neck extension -individuals will be taught to place their dominant hand posterior to their head at occiput. Then, they will be told to firmly push the head backwards against that hand, and hold for five seconds and repeat 5 times. • Participants will be asked to place the right hand flat on the same side of the head. Next.~they will be instructed to firmly push the head against right hand and hold for 5 seconds and repeat five times. Same exercise will be repeated with the left hand against the left side of the head as well.~• Participants will be taught to place their right hand on their right cheek. Then, they will be told to rum the face against the right hand and wait for 5 seconds and repeat five times. Same exercise was repeated with the left hand on the left cheek as well.
Study NCT05356676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Therapy
Description: 1. In supine position, the patient will be instructed to take a deep breath in order to relax the body whilst holding his/her shoulders and neck in a comfortable posture.~2. the patient will bend his/her knees and place their feet flat on the floor, and will hold the posture without any other neck movement. Then the patient will be asked to raise their dominant arm to 90° shoulder flexion along with full elbow extension and scapular protraction.~   This posture will be held for 10 seconds before returning to the prior position with 3 laps, 10 repetitions with a one-minute break between.~3. in quadruped position, the patient will lift up their arms alternatively with shoulder abduction and 120 ° flexion. This posture will be held for 10 seconds before returning to the starting position for three laps, 10 repetitions with a 30-second break in between. Participants will be instructed to perform these for 3 times a week for 4 weeks.
Study NCT06609187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNC-077
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT04885166 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Web-based placebo presentation
Description: This presentation will discuss the prevalence of psychological disorders in college students, their etiologies, psychiatric medications, and students' personal experiences navigating college with a diagnosis of an anxiety and learning disorder, respectively. Attention-deficit/hyperactivity disorder and stimulant medications will be addressed, but diversion and medication misuse will not be discussed.
Study NCT04885166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based simulation active intervention
Description: This intervention engages students in interactive discussions with virtual humans to (a) learn about the actual prevalence of NMUPS and diversion and their related risks, (b) practice using refusal strategies when approached for their medication in high-risk situations, and (c) understand how to effectively communicate with prescribers and avoid medication misuse.
Study NCT04724759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine / Ketamine / Lidocaine
Description: Patients in this group will receive an infusion of lidocaine, ketamine, or dexmedetomidine supplemented with other intravenous analgesics and intravenous and inhaled anesthetics, as needed clinically. This includes administration of 5 mcg/kg/min of ketamine plus 0.5 - 1.0 µg/kg/hr of dexmedetomidine (Precedex) as a continuous infusion, started from induction to stop one hour before surgery is anticipated to end.
Study NCT06187766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Social Media Addiction
Description: Social Media Addiction level will be determined by Bergen Social Media Addiction Scale
Study NCT06590064 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive Blood Pressure Measurement
Description: Non-invasive Blood Pressure Measurement in Both Upper and Lower Limbs
Study NCT06587789 — intervention group
Intervention type: DRUG
Intervention: Ribociclib
Description: Participants will receive ribociclib (at a dose of 400mg per day for 3 weeks, followed by 1 week off, 4 weeks for 1 cycle) plus physician-selected endocrine therapy (according to standard clinical practice, TAM or AI, with or without OFS).
Study NCT06665022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: A neuroConn MR-safe 1x1 tDCS stimulator will be used to apply 12 minutes of 2.0 mA electrical current, with 30 seconds ramps up and 30 seconds ramps down. The electrical current will be applied by using two carbon rubber electrodes (one anode, one cathode) with added ten20 conductive paste. The electrode+paste will be affixed on the participant's scalp over the frontal cortices at F3 and F4 location (EEG 10-20 system). Inflow of current (anode) will occur at F4 location, and outflow of current will occur at F3 (cathode). For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
Study NCT06114914 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tap Talk online program
Description: Online hand and speech motor testing
Study NCT06086704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorofuranylnorprogesterone
Description: 18F-FFNP will be given by a slow infusion (approximately 2 minutes), and the dose administered will be approximately 7 mCi.
Study NCT06019598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Licorice
Description: Ecologic sweet licorice pastilles made from Glycyrrhiza glabra grown in Calabria, Italy, with a GA content of 29.9 ±2.0 mg/g.
Study NCT06665022 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Sham stimulation will be performed with the same 1x1 device. Participants will receive 2 mA of direct current stimulation for 30 seconds with 30 seconds ramps up and down. This provides the tingling and prickling sensation on the scalp associated with tDCS while prevent delivering sufficient current (12 minutes) to penetrate the skull and stimulate the brain. Prep in sham conditions will be identical to active stimulation conditions. For each stimulation condition (active, sham), each participant will perform two runs of N-back working memory task (baseline/pre-stimulation and during stimulation). Sham efficacy will be evaluated as a direct comparison in N-back performance and connectivity results in active group versus sham group.
Study NCT04630158 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SAF312 Placebo
Description: Topical ocular, suspension eye drops
Study NCT04630158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAF312
Description: Topical ocular, suspension eye drops
Study NCT05886387 — intervention group
Intervention type: OTHER
Intervention: High PEEP + Recruitment maneuvers
Description: The use of a High PEEP (positive end-expiratory pressure) level after recruiting collapsed alveoli can protect from mechanical ventilation associated lung injury
Study NCT05886387 — intervention group
Intervention type: OTHER
Intervention: Standard PEEP. Low positive end-expriatory pressure
Description: Mechanical ventilation is managed with a low standard PEEP without recruitment manneuvers
Study NCT06086704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positron Emissions Tomography / Magnetic Resonance Imaging
Description: Breast specific PET/MRI data will be acquired using a 3T simultaneous PET/MRI scanner (Signa PET/MR, GE Healthcare)
Study NCT04496115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness training
Study NCT05396521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Group 2 (experimental) will receive standard of care physical therapy to be done with blood flow restriction therapy (BFR). This method includes standard of care physical therapy while occluding blood flow.
Study NCT05396521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Physical Therapy
Description: Group 1 (Control) will receive standard of care physical therapy.
Study NCT04762498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: IV dose of pegloticase q4 weeks co-administered with weekly oral methotrexate
Study NCT04762498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: 15 mg oral dose methotrexate administered weekly
Study NCT06365918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG2025
Description: Given by Intraperitoneal
Study NCT06077838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RELAXaHEAD Smartphone App Version 1
Description: RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts.
Study NCT06696599 — intervention group
Intervention type: PROCEDURE
Intervention: Serum and corporal irisin
Description: measure serum and corporal irisin
Study NCT06698692 — intervention group
Intervention type: DRUG
Intervention: Trilaciclib Injection [Cosela]
Description: Trilaciclib Combined chemoradiotherapy
Study NCT06699745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: In studies, white noise was used as a sedative in infants. It was not used in older children. In school-age children, white noise will be used to reduce fear, anxiety and pain during the endoscopy procedure.
Study NCT06699745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: white noise intervention
Description: White noise will be played at a decibel level appropriate for the children in the group.
Study NCT06699329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide Decanoate
Description: multiple doses, oral tablet
Study NCT06699329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: multiple doses, oral tablet
Study NCT06699459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome
Description: ②LV: 400mg/m2, intravenous infusion, Q2W, d1; ③5-FU: 2400 mg/m2, continuous intravenous infusion, Q2W, d1-2;
Study NCT06699459 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: ① Capecitabine, 1250mg/m2 orally, bid, Q3W, d1-14;
Study NCT06699498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benmelstobart
Description: 1200mg, D1, IV,q3w
Study NCT06699498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 10mg，D1-14，po，q3w
Study NCT06699498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60mg/m2， D1， IV，q3w
Study NCT06699498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection （Albumin Bound）
Description: 260mg/m2，IVgtt ，D1，q3w
Study NCT06698354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Assisted Hypnotherapy
Description: Virtual Reality-Assisted Hypnotherapy utilizes HypnoVR software delivered through VR glasses to provide a relaxing virtual environment. The intervention is integrated into a standard physical therapy program, with participants receiving 20-minute VR-assisted hypnotherapy sessions during each of the 15 supervised physical therapy sessions over a 3-week period. This approach aims to improve pain management, quality of life, and adherence to treatment in patients with chronic low back pain.
Study NCT06698354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Participants in the control group will undergo a standard physical therapy program focused on the cervical region, consisting of 15 sessions over 3 weeks. Each session will be supervised by physiotherapists in a clinical setting and will include traditional physical therapy techniques such as therapeutic exercises
Study NCT06699303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g / 100 g for infants in the control group in diaper dermatitis care
Description: In diaper dermatitis care, it was planned to use their mothers' milk for the babies in the experimental group and diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100g for the babies in the control group. The reason why diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g is preferred is that it is the most frequently used cream in cases of uncomplicated diaper dermatitis. The mothers of the babies in the control group will be asked to wash and dry the baby's diaper with soap and water during each diaper change and then apply diaper rash cream containing Hamamelis virginiana (potency 12mg/100g) 5.35 g/100 g. Mothers will be asked to record any new signs and symptoms that develop during the treatment and to inform the investigators will be asked to provide information. Positive and negative effects of treatment will also be recorded.
Study NCT06442748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.
Study NCT06442748 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Levetiracetam
Description: Levetiracetam is usually preferred in brain tumor-related epilepsy. Levetiracetam is a second-generation antiepileptic drug that binds to synaptic vesicle glycoprotein SV2A, which interferes with the release of neurotransmitters from the synaptic vesicle and control seizure by multiple mechanisms.
Study NCT06424340 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-dNPM1-TCR.1
Description: T Cell Receptor (TCR) T cell therapy
Study NCT05620979 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Providing financial navigation via active navigation, ad hoc navigation or no study-based navigation.
Description: Providing financial navigation to blood cancer survivors.
Study NCT06077838 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RELAXaHEAD Smartphone App Version 2
Description: RELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts. This version also contains audio materials.
Study NCT06086704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: hormone based chemotherapy that reduces estrogen, 1 mg anastrozole once daily by mouth for a minimum of 14 days
Study NCT06086704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: Venous blood samples will be collected at multiple timepoints (e.g., 5, 10, 20, 30, and 45 min after 18F-FFNP injection to determine parent and metabolite fractions
Study NCT06086704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDA-approved gadolinium-based intravenous contrast agent
Description: FDA-approved gadolinium-based intravenous contrast agent used for the MRI portion of this study
Study NCT06281652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Go classes
Description: Classes of board games (Go), performed in groups of 6-10 subjects, once a week
Study NCT06281652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chess classes
Description: Classes of board games (Chess), performed in groups of 6-10 subjects, once a week
Study NCT04192773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Lidocaine
Description: IV lidocaine will be administered pre-fMRI and post-FMRI with each subject acting as their own control
Study NCT05688202 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous combination of fractional CO2 laser and subcision
Description: Fractional CO2 laser is performed immediately following subcision. Subcision is operated in all participants using an 181/2G Nokor needle (BD Nokor™ Admix Needles, United States). The insertion depth is at the dermal-hypodermal junction. The subcision needle is advanced and retracted in a tunneling motion to penetrate the fibrotic scar tissue, then slid in a direction parallel to the skin's surface in order to detach the scar from its tethers.~All participants undergo FrCO2 laser (10 600-nm eCO2 laser, Lutronic Corporation, Goyang, Korea) with the parameters following the suggested regimen at static mode: 120 μm beam size, 30 W peak power, 30 - 120 mJ pulse energy, 50-75 spots/cm2 density, with two passes: (1)Only the atrophic scars are treated using a 4mm square or circle pattern, 100-120 mJ pulse energy, and 50 spots/cm2 density. (2)The whole half side of the face is treated using a 12mm square pattern, 30-40 mJ pulse energy, and 75 spots/cm2 density, \<10% overlap.